The aim of this study was to evaluate the clinical value of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) in advanced liver alveolar echinococcosis (LAE) prior to and following autologous liver transplantation (ALT). The biodistribution of lesions in 8 patients was recorded using 18F-FDG PET/CT prior to and following surgery. The maximum standardized uptake value (SUVmax) of the lesions was also measured and compared with the pathological results. The overall hepatic peri-lesion SUVmax of the patients was 3.57±1.21, and the delayed SUVmax was 4.19±1.70. The diagnostic sensitivity of 18F-FDG PET/CT in LAE was 91.67%, with a specificity of 60.00% and accuracy of 82.35%. The positive predictive value was 84.62%, and the negative predictive value was 75.00%. SUVmax values of the surviving liver were 1.23±0.78 after 1 month, 1.15±0.67 after 3 months and 0.85±0.35 after 6 months. Compared with normal liver values (0.95±0.19), the 1-month SUVmax was significantly different. The SUVmax in 3 patients with high-lividity lesions was 2.05±0.72, and the delayed SUVmax was 3.15±0.83; 3 months after transplantation, the SUVmax was 1.85±0.62, and the delayed SUVmax was 2.95±0.79, revealing no significant difference. In conclusion, 18F-FDG PET/CT is effective for determining the biological boundary of LAE and shows important clinical value in determining the metabolic activities of the surviving liver following ALT.

The aim of this study was to monitor the drug release of ibuprofen sustained-release capsules in real time in situ. A mathematical separation model of dynamic three-wavelength K-ratio spectrophotometry was established to eliminate the interference of gelatin capsule shells when drug release was monitored by a fiber-optic drug dissolution in situ test system. A control experiment with high performance liquid chromatography was performed simultaneously. Within 7 h, real-time drug release profiles were obtained. The average drug release rates were 19.79%, 37.34%, 63.13%, and 88.41% by the fiber-optic drug dissolution in situ test system at the respective time points of 1 h, 2 h, 4 h, and 7 h. There were no significant differences between the in situ and control methods. Drug release of ibuprofen sustained-release capsules can be monitored by the fiber-optic drug dissolution in situ test system assisted by the mathematical separation model of dynamic three-wavelength K-ratio spectrophotometry. Information about the entire dissolution process can be produced by the real-time release profile.

The value of dual imaging mode for the severity assessment of Parkinson disease (PD) is explored by conducting positron emission tomography computed tomography (PET/CT) double imaging using combined 18-fluorine flurodeoxyglucose ( 18 F-FDG) brain metabolism and 11C-2β-carbomethoxy-3β-(4-fluorophenyl) tropane ( 11 C-CFT) brain dopamine transporter (DAT). A total of 102 patients with PD and 50 healthy people in the control group are enrolled for the PET/CT dual imaging of 18 F-FDG brain metabolism and 11 C-CFT brain DAT. The characteristics of 18 F-FDG PET/CT and 11 C-CFT PET/CT imaging are analyzed by delineating the region of interest. Differences in the glucose metabolism and DAT distribution in the basal ganglia of patients with PD and healthy control group in the PET/CT imaging and the radioactive distribution characteristics of cerebral cortex in glucose metabolism imaging are compared. The characteristics of PET/CT imaging of 11 C-CFT brain DAT in the ganglion region in absorbing 11 C-CFT in different PD groups are analyzed. Compared with the healthy control group, changes in the cerebral glucose metabolism in the PD group mainly occur due to the increased symmetry metabolism of the nucleus of bilateral basal ganglia and the decreased metabolism of the cerebral cortex as shown in the 18 F-FDG PET/CT images. With disease progression, the bilateral parietal, frontal, temporal, and occipital leaves showed different degrees of FDG metabolism. Statistically significant difference is observed for the 11 C-CFT absorption among the caudate nucleus and the anterior, middle, and posterior nuclei of the bilateral basal ganglia of the PD and healthy control groups. In the PD group, the bilateral caudate nucleus and the anterior, middle, and posterior parts of the putamen show decreased DAT distribution. Regardless of unilateral or bilateral symptoms, the DAT distribution in the nucleus of the contralateral basal ganglia and in the posterior part of the nucleus is substantially reduced. PET/CT dual imaging by 18 F-FDG PET/CT combined with 11 C-CFT PET/CT features high application value for the severity assessment of PD.